JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB120718

AMD3100 octahydrochloride, CXCR4 antagonist

Be the first to review this product! Submit a review

|

(26 Publications)

MW 794.5 Da, Purity >99%. Plerixafor (hydrochloride) is a macrocyclic compound that acts as an irreversible antagonist against the binding of CXCR4 with its ligand, SDF-​1 (CXCL12).

It suppresses infection by HIV with an IC50 value of 1-​10 ng/ml with selectivity toward CXCR4-​tropic virus. Plerixafor mobilizes hematopoietic stem and progenitor cells for transplant better than G-​CSF alone. It also increases T-​cell trafficking in the blood and spleen as well as the central nervous system. Plerixafor regulates the growth of primary and metastic breast cancer cells and inhibits dissemination of ovarian carcinoma cells.

.

View Alternative Names

C-X-C chemokine receptor type 4, CD184, CD184 antigen, CXCR4_HUMAN, Chemokine (C X C motif) receptor 4, Chemokine CXC Motif Receptor 4, D2S201E, FB22, Fusin, HM89, HSY3RR, LCR1, LESTR, Leukocyte-derived seven transmembrane domain receptor, Lipopolysaccharide associated protein 3, NPY3R, NPYR, NPYRL, NPYY3, NPYY3R, Neuropeptide Y receptor Y3, Probable G protein coupled receptor lcr1 homolog, SDF-1 receptor, SEVEN-TRANSMEMBRANE-SEGMENT RECEPTOR, Stromal cell-derived factor 1 receptor, WHIM, WHIMS

2 Images
Chemical Structure - AMD3100 octahydrochloride, CXCR4 antagonist (AB120718)
  • Chemical Structure

Lab

Chemical Structure - AMD3100 octahydrochloride, CXCR4 antagonist (AB120718)

2D chemical structure image of ab120718, AMD3100 octahydrochloride, CXCR4 antagonist

Cellular Activation - AMD3100 octahydrochloride, CXCR4 antagonist (AB120718)
  • CellAct

Unknown

Cellular Activation - AMD3100 octahydrochloride, CXCR4 antagonist (AB120718)

Uninfected control DCs were treated with MeAIB, MSO, inhibitors of CXCR4 (AMD3100), PI3K (LY294002, ab120243) or Rho kinase (Y27632, ab120129), or Gln starvation for 2 hours before assessing migration to 100 ng/ml SDF-1 α. Chemotactic index (CI) is defined as the fold increase in the number of migrating DCs to SDF-1 α over the spontaneous migration. One-way ANOVA reveals an effect of pharmacological treatments on the SDF-1 α-induced migration (F(6,44) = 6.700, P<0.001). Asterisks indicate P<0.05 (Dunnett's post hoc).

Image from Lee IP, et al. Plos One, 9(10), e109803. Fig 3B,; doi: 10.1371/journal.pone.0109803

Key facts

CAS number

155148-31-5

Purity

>99%

Form

Solid

form

Molecular weight

794.5 Da

Molecular formula

C<sub>2</sub><sub>8</sub>H<sub>6</sub><sub>2</sub>Cl<sub>8</sub>N<sub>8</sub>

PubChem

65014

Nature

Synthetic

Solubility

Soluble in PBS, pH 7.2, at 10 mg/ml.

Biochemical name

Plerixafor Octahydrochloride

Biological description

Plerixafor (hydrochloride) is a macrocyclic compound that acts as an irreversible antagonist against the binding of CXCR4 with its ligand, SDF-​1 (CXCL12).

It suppresses infection by HIV with an IC50 value of 1-​10 ng/ml with selectivity toward CXCR4-​tropic virus. Plerixafor mobilizes hematopoietic stem and progenitor cells for transplant better than G-​CSF alone. It also increases T-​cell trafficking in the blood and spleen as well as the central nervous system. Plerixafor regulates the growth of primary and metastic breast cancer cells and inhibits dissemination of ovarian carcinoma cells.

Canonical smiles

C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3.Cl.Cl.Cl.Cl.Cl.Cl.Cl.Cl

InChi

InChI=1S/C28H54N8.8ClH/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36;;;;;;;;/h5-8,29-34H,1-4,9-26H2;8*1H

InChiKey

UEUPDYPUTTUXLJ-UHFFFAOYSA-N

IUPAC Name

1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane;octahydrochloride

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Storage information
Store under desiccating conditions|The product can be stored for up to 12 months

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CXCR4 also known as C-X-C chemokine receptor type 4 is a G protein-coupled receptor that is involved in signal transduction. It has a molecular weight of approximately 41 kDa. CXCR4 is ubiquitously expressed across various tissues including immune cells like T and B lymphocytes as well as in bone marrow brain and heart. It binds specifically with the ligand CXCL12 also known as stromal cell-derived factor 1 (SDF-1) facilitating responses such as cell migration and proliferation.
Biological function summary

CXCR4 plays an important role in the immune system hematopoiesis and angiogenesis. It does not function alone and is often part of a larger protein complex where it recruits and activates other G proteins. The receptor mediates chemotactic responses directing cells to sites of inflammation or injury. Its interaction with CXCL12 is critical for maintaining immune surveillance aiding in the movement and positioning of immune cells.

Pathways

CXCR4 integrates into significant cellular signaling pathways such as the PI3K/AKT pathway and the MAPK pathway. It collaborates closely with signaling proteins like AKT1 and MAPK1 impacting cell survival and growth. These pathways are essential for various cellular functions including cell cycle progression and apoptosis regulation. The cross-talk between CXCR4 and these pathways underlines its influence on cell fate decisions.

CXCR4 is implicated in cancer metastasis and HIV entry into cells. Overexpression of CXCR4 is observed in several cancers contributing to tumor growth and metastasis. The interaction between CXCR4 and CXCL12 facilitates the infiltration and spread of cancer cells. Additionally in HIV CXCR4 serves as a coreceptor along with CD4 allowing the virus to enter and infect host cells. Both cancer and HIV illustrate CXCR4's central role in disease progression and pathogenesis.

Product protocols

Publications (26)

Recent publications for all applications. Explore the full list and refine your search

Journal for immunotherapy of cancer 12: PubMed39562007

2024

TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion.

Applications

Unspecified application

Species

Unspecified reactive species

Anais Debesset,Caroline Pilon,Sylvain Meunier,Orianne Cuelenaere-Bonizec,Wilfrid Richer,Allan Thiolat,Claire Houppe,Matteo Ponzo,Jeanne Magnan,Jonathan Caron,Pamela Caudana,Jimena Tosello Boari,Sylvain Baulande,Nhu Han To,Benoit Laurent Salomon,Eliane Piaggio,Ilaria Cascone,José Laurent Cohen

The Journal of experimental medicine 221: PubMed38393304

2024

CXCL12+ dermal fibroblasts promote neutrophil recruitment and host defense by recognition of IL-17.

Applications

Unspecified application

Species

Unspecified reactive species

Kellen J Cavagnero,Fengwu Li,Tatsuya Dokoshi,Teruaki Nakatsuji,Alan M O'Neill,Carlos Aguilera,Edward Liu,Michael Shia,Olive Osuoji,Tissa Hata,Richard L Gallo

Frontiers in physiology 15:1349119 PubMed38370015

2024

Modeling the SDF-1/CXCR4 protein using advanced artificial intelligence and antagonist screening for Japanese anchovy.

Applications

Unspecified application

Species

Unspecified reactive species

Issei Yahiro,Kyle Dominic Eguid Barnuevo,Oga Sato,Sipra Mohapatra,Atsushi Toyoda,Takehiko Itoh,Kaoru Ohno,Michiya Matsuyama,Tapas Chakraborty,Kohei Ohta

Oncoimmunology 11:2027136 PubMed35127250

2022

Impaired CXCL12 signaling contributes to resistance of pancreatic cancer subpopulations to T cell-mediated cytotoxicity.

Applications

Unspecified application

Species

Unspecified reactive species

Yuan-Na Lin,Marcel O Schmidt,Ghada M Sharif,Eveline E Vietsch,Amber J Kiliti,Megan E Barefoot,Anna T Riegel,Anton Wellstein

Science (New York, N.Y.) 373: PubMed34083447

2021

Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma.

Applications

Unspecified application

Species

Unspecified reactive species

Andrea Cugurra,Tornike Mamuladze,Justin Rustenhoven,Taitea Dykstra,Giorgi Beroshvili,Zev J Greenberg,Wendy Baker,Zach Papadopoulos,Antoine Drieu,Susan Blackburn,Mitsuhiro Kanamori,Simone Brioschi,Jasmin Herz,Laura G Schuettpelz,Marco Colonna,Igor Smirnov,Jonathan Kipnis

BioMed research international 2021:8852574 PubMed34136574

2021

Inhibition of SDF-1/CXCR4 Axis to Alleviate Abnormal Bone Formation and Angiogenesis Could Improve the Subchondral Bone Microenvironment in Osteoarthritis.

Applications

Unspecified application

Species

Unspecified reactive species

Hanjun Qin,Xingqi Zhao,Yan Jun Hu,Shengnan Wang,Yunfei Ma,Siying He,Ke Shen,Haoyang Wan,Zhuang Cui,Bin Yu

PloS one 15:e0232536 PubMed32353075

2020

Stromal cell-derived factor 1 regulates in vitro sperm migration towards the cumulus-oocyte complex in cattle.

Applications

Unspecified application

Species

Unspecified reactive species

Kohei Umezu,Kenshiro Hara,Yuuki Hiradate,Takashi Numabe,Kentaro Tanemura

American journal of physiology. Heart and circulatory physiology 318:H1420-H1435 PubMed32330088

2020

TLR2/CXCR4 coassociation facilitates infection-induced atherosclerosis.

Applications

Unspecified application

Species

Unspecified reactive species

Guolin Miao,Xi Zhao,Beibei Wang,Lijun Zhang,Guangyan Wang,Ningbo Zheng,Jingya Liu,Zhelong Xu,Lijun Zhang

American journal of physiology. Renal physiology 318:F741-F753 PubMed32068458

2020

Biphasic MIF and SDF1 expression during podocyte injury promote CD44-mediated glomerular parietal cell migration in focal segmental glomerulosclerosis.

Applications

Unspecified application

Species

Unspecified reactive species

Naoko Ito,Kazuo Sakamoto,Chihiro Hikichi,Taiji Matsusaka,Michio Nagata

Frontiers in pharmacology 10:1554 PubMed32038242

2020

AMD3100 Attenuates Post-Traumatic Osteoarthritis by Maintaining Transforming Growth Factor-β1-Induced Expression of Tissue Inhibitor of Metalloproteinase-3 the Phosphatidylinositol 3-Kinase/Akt Pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Weiwei Lu,Zhiyi He,Jia Shi,Zhenggang Wang,Wei Wu,Jian Liu,Hao Kang,Feng Li,Shuang Liang
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com